Scancell merges with Nasdaq shell Neuphoria to fund USD 89m Phase III melanoma trial
UK-based Scancell Holdings plc has announced an all-share merger agreement with Neuphoria Therapeutics Inc., a move that will provide Scancell with a Nasdaq listing and up to $89 million in financing. This funding is earmarked for the registrational Phase III development of Scancell's melanoma …